

【Therapeutic category】 Other antitumor agents

【Non-proprietary name】 Tucatinib ethanolate

【Safety measure】 PRECAUTIONS should be revised.

A revised description is underlined.

Current	Revision
2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.) Patients receiving the following drugs: Venetoclax (chronic lymphocytic leukaemia (including small lymphocytic lymphoma) and relapsed or refractory mantle cell lymphoma during the dose escalation phase), anamorelin hydrochloride, voclosporin, ivabradine hydrochloride, quinidine sulfate hydrate, ticagrelor, mavacamten, rivaroxaban, azelnidipine, olmesartan edoxomil/azelnidipine, eplerenone, ergotamine tartrate/anhydrous caffeine/isopropylantipyrine, simvastatin, tadalafil (Adcirca), macitentan/tadalafil, finerenone, lomitapide mesilate, suvorexant, daridorexant hydrochloride, triazolam, blonanserin, vornorexant hydrate, lurasidone hydrochloride, vardenafil hydrochloride hydrate, methylethylergometrine maleate, lonafarnib, ibrutinib	2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.) Patients receiving the following drugs: Venetoclax (chronic lymphocytic leukaemia (including small lymphocytic lymphoma) and relapsed or refractory mantle cell lymphoma during the dose escalation phase), anamorelin hydrochloride, voclosporin, ivabradine hydrochloride, quinidine sulfate hydrate, ticagrelor, mavacamten, rivaroxaban, azelnidipine, olmesartan edoxomil/azelnidipine, eplerenone, ergotamine tartrate/anhydrous caffeine/isopropylantipyrine, simvastatin, tadalafil (Adcirca), macitentan/tadalafil, finerenone, lomitapide mesilate, suvorexant, daridorexant hydrochloride, triazolam, blonanserin, vornorexant hydrate, lurasidone hydrochloride, vardenafil hydrochloride hydrate, methylethylergometrine maleate, lonafarnib, ibrutinib, <u>palovarotene</u>

10. INTERACTIONS			10. INTERACTIONS		
10.1 Contraindications for Co-administration (Do not co-administer with the following)			10.1 Contraindications for Co-administration (Do not co-administer with the following)		
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors
Anamorelin hydrochloride Voclosporin Ivabradine hydrochloride Quinidine sulfate hydrate Ticagrelor Mavacamten Rivaroxaban Azelnidipine Olmesartan medoxomil/azelnidipine Eplerenone Ergotamine tartrate/anhydrous caffeine/isopropylantipyrine Simvastatin Tadalafil (Adcirca) Macitentan/tadalafil Finerenone Lomitapide mesilate Suvorexant	The adverse reactions associated with these drugs may be enhanced.	Because this drug strongly inhibits CYP3A, blood concentrations of these drugs may increase.	Anamorelin hydrochloride Voclosporin Ivabradine hydrochloride Quinidine sulfate hydrate Ticagrelor Mavacamten Rivaroxaban Azelnidipine Olmesartan medoxomil/azelnidipine Eplerenone Ergotamine tartrate/anhydrous caffeine/isopropylantipyrine Simvastatin Tadalafil (Adcirca) Macitentan/tadalafil Finerenone Lomitapide mesilate Suvorexant	The adverse reactions associated with these drugs may be enhanced.	Because this drug strongly inhibits CYP3A, blood concentrations of these drugs may increase.

This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Daridorexant hydrochloride Triazolam Blonanserin Lurasidone hydrochloride Vardenafil hydrochloride hydrate Methylethergometrine maleate Lonafarnib Ibrutinib			Daridorexant hydrochloride Triazolam Blonanserin Lurasidone hydrochloride Vardenafil hydrochloride hydrate Methylethergometrine maleate Lonafarnib Ibrutinib <u>Palovarotene</u>		

N/A: Not Applicable. No corresponding description is included in the current PRECAUTIONS.

This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.